Later studies propose a different classification system based on IDH (Isocitrate dehydrogenase) gene mutation status: tumors classified as IDH wild-type, IDH mutant, and patients whose full IDH analysis cannot be determined called GBM NOS (not otherwise specified) [1]. This evidence concerns the gene IDH1 and glioblastoma.